The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.
Abstract
Nonalcoholic steatohepatitis (NASH) is currently the third leading indication for liver transplantation (LT) in the U.S. and is predicted to become the leading indication for LT in the near future. The trends in NASH-related hepatocellular carcinoma (HCC) among LT recipients in the U.S. remain undefined. We performed a retrospective cohort study to evaluate trends in the etiology of HCC among adult LT recipients in the U.S. from 2002 to 2012, using national data from the United Network for Organ Sharing registry. From 2002-2012, there were 61,868 adults who underwent LT in the U.S., including 10,061 patients with HCC. The total number and proportion of HCC LT recipients demonstrated a significant increase following the implementation of the Model for Endstage Liver Disease (MELD) scoring system in 2002 (3.3%, n = 143 in 2000 versus 12.2%, n = 714 in 2005 versus 23.3%, n = 1336 in 2012). The proportion of hepatitis C virus (HCV)-related HCC increased steadily from 2002 to 2012, and HCV remained the leading etiology of HCC throughout the MELD era (43.4% in 2002 versus 46.3% in 2007 versus 49.9% in 2012). NASH-related HCC also increased significantly, and NASH is the second leading etiology of HCC-related LT (8.3% in 2002 versus 10.3% in 2007 versus 13.5% in 2012). From 2002 to 2012, the number of patients undergoing LT for HCC secondary to NASH increased by nearly 4-fold, and the number of LT patients with HCC secondary to HCV increased by 2-fold. Conclusion: NASH is the second leading etiology of HCC leading to LT in the U.S. More important, NASH is currently the most rapidly growing indication for LT in patients with HCC in the U.S. (Hepatology 2014;59:2188–2195)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Malinchoc, M., Kamath, P. S., Gordon, F. D., Peine, C. J., Rank, J., & ter Borg, P. C. J. (2000) · Hepatology · doi:10.1053/he.2000.5852 · Cited by 2,893
White, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766
Kawamura, Y., Arase, Y., Ikeda, K., Seko, Y., Imai, N., Hosaka, T., Kobayashi, M., Saitoh, S., Sezaki, H., Akuta, N., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.327 · Cited by 280 · cited 2×
“lower rate of HCC development among NASH patients has been reported in several additional studies.(10-17) Despite the low incidence of HCC among NASH patients, the overall increasing prevalence of NAFLD will undoubtedly lead to increased prevalence of NASH and a subsequent increased prevalence of NASH-related HCC.”
BackgroundResult
Cited by
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Global burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Zhang, X., Coker, O. O., Chu, E. S., Fu, K., Lau, H. C. H., Wang, Y.-X., Chan, A. W. H., Wei, H., Yang, X., Sung, J. J. Y., et al. (2021) · Gut · doi:10.1136/gutjnl-2019-319664 · Cited by 841
Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease
Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P. A., Li, L., Desiderio, R., Thrift, A. P., Asch, S. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.024 · Cited by 795
Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review
Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776
Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.011 · Cited by 583
Past, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p056002 · Cited by 372
Epidemiology and risk-stratification of NAFLD-associated HCC
Ioannou, G. N. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.012 · Cited by 361
Stine, J. G., Wentworth, B. J., Zimmet, A., Rinella, M. E., Loomba, R., Caldwell, S. H., & Argo, C. K. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14937 · Cited by 336
Haldar, D., Kern, B., Hodson, J., Armstrong, M. J., Adam, R., Berlakovich, G., Fritz, J., Feurstein, B., Popp, W., Karam, V., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.011 · Cited by 313
Gastrointestinal Complications of Obesity
Camilleri, M., Malhi, H., & Acosta, A. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.052 · Cited by 269
Llorente, C., Jepsen, P., Inamine, T., Wang, L., Bluemel, S., Wang, H. J., Loomba, R., Bajaj, J. S., Schubert, M. L., Sikaroodi, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00796-x · Cited by 257
Non‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management
Huang, T. (., Behary, J., & Zekry, A. (2020) · Internal Medicine Journal · doi:10.1111/imj.14709 · Cited by 227
Lee, Y.-S., Kim, S. Y., Ko, E., Lee, J.-H., Yi, H.-S., Yoo, Y. J., Je, J., Suh, S. J., Jung, Y. K., Kim, J. H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03389-2 · Cited by 233
Physiopathology of the Permeability Transition Pore: Molecular Mechanisms in Human Pathology
Bonora, M., Patergnani, S., Ramaccini, D., Morciano, G., Pedriali, G., Kahsay, A., Bouhamida, E., Giorgi, C., Wieckowski, M., & Pinton, P. (2020) · Biomolecules · doi:10.3390/biom10070998 · Cited by 135
Pais, R., Fartoux, L., Goumard, C., Scatton, O., Wendum, D., Rosmorduc, O., & Ratziu, V. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14261 · Cited by 129
Soto-Angona, Ó., Anmella, G., Valdés-Florido, M. J., De Uribe-Viloria, N., Carvalho, A. F., Penninx, B. W. J. H., & Berk, M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01713-8 · Cited by 122
Motamed, N., Rabiee, B., Hemasi, G. R., Ajdarkosh, H., Khonsari, M. R., Maadi, M., Keyvani, H., & Zamani, F. (2016) · Hepatitis Monthly · doi:10.5812/hepatmon.39575 · Cited by 80
Should patients with NAFLD/NASH Be surveyed for HCC?
Reig, M., Gambato, M., Man, N. K., Roberts, J. P., Victor, D., Orci, L. A., & Toso, C. (2019) · Transplantation · doi:10.1097/tp.0000000000002361 · Cited by 71
Bhurwal, A., Ratta, P., Yoshitake, S., Pioppo, L., Reja, D., Dellatore, P., & Rustgi, V. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-805 · Cited by 61
Kennedy-Martin, T., Bae, J. P., Paczkowski, R., & Freeman, E. (2018) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-018-0052-7 · Cited by 61
Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma
Koo, S.-Y., Park, E.-J., & Lee, C.-W. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0480-3 · Cited by 47
Goldberg, D., Mantero, A., Newcomb, C., Delgado, C., Forde, K. A., Kaplan, D. E., John, B., Nuchovich, N., Dominguez, B., Emanuel, E., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.021 · Cited by 38
Lipid droplets disrupt mechanosensing in human hepatocytes
Chin, L., Theise, N. D., Loneker, A. E., Janmey, P. A., & Wells, R. G. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00098.2020 · Cited by 38
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
Kannt, A., Madsen, A. N., Kammermeier, C., Elvert, R., Klöckener, T., Bossart, M., Haack, T., Evers, A., Lorenz, K., Hennerici, W., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14035 · Cited by 37
The association of nonalcoholic steatohepatitis and obstructive sleep apnea
Asfari, M. M., Niyazi, F., Lopez, R., Dasarathy, S., & McCullough, A. J. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000973 · Cited by 25
Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States
Wallace, C., Gamkrelidze, I., Estes, C., Razavi, H., & Sanyal, A. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.009 · Cited by 27
Maleki, I. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i35.12566 · Cited by 22
Yanagisawa, H., Maeda, H., Noguchi, I., Tanaka, M., Wada, N., Nagasaki, T., Kobayashi, K., Kanazawa, G., Taguchi, K., Chuang, V. T. G., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103314 · Cited by 10
Metadata
- Authors
- Wong, R. J., Cheung, R., & Ahmed, A.
- Venue
- Hepatology
- Published
- 2014-06
- Volume
- 59
- Issue
- 6
- Pages
- 2188-2195
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2076244923
- Cited by
- 723
- References
- 4
- FWCI
- 24.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.